Cytokine determinants of viral tropism

Nature Reviews Immunology

Volumn 9, Issue 9, 2009, Pages 645-655

  McFadden, Grant ^a   Mohamed, Mohamed R ^a   Rahman, Masmudur M ^a   Bartee, Eric ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; CYTOKINE; GAMMA INTERFERON; INTERFERON; JANUS KINASE 1; PROTEIN TYROSINE KINASE; STAT1 PROTEIN; STAT2 PROTEIN; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA;

CANCER THERAPY; DENDRITIC CELL; H-1 PARVOVIRUS; HEPATITIS B VIRUS; HOST PATHOGEN INTERACTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOREGULATION; INFLUENZA VIRUS A; INNATE IMMUNITY; MYXOMA VIRUS; NONHUMAN; OLIGODENDROGLIA; PATHOGENESIS; PREVALENCE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REVIEW; SIGNAL TRANSDUCTION; VIROGENESIS; VIROTHERAPY; VIRUS INFECTION; VIRUS REPLICATION; ZOONOSIS; ANIMAL; IMMUNOLOGY; METABOLISM; ONCOLYTIC VIROTHERAPY; PLANT GROWTH; VIRUS;

ANIMALS; CYTOKINES; HUMANS; INTERFERONS; ONCOLYTIC VIROTHERAPY; TROPISM; TUMOR NECROSIS FACTOR-ALPHA; VIRUSES;

EID: 70249134047     PISSN: 14741733     EISSN: None     Source Type: Journal    
DOI: 10.1038/nri2623     Document Type: Review

References (121)

1. Brandenburg, B. & Zhuang, X. Virus trafficking - learning from single-virus tracking. Nature Rev. Microbiol. 5, 197-208 (2007).
2. Hickman, H. D., Bennink, J. R. & Yewdell, J. W. Caught in the act: intravital multiphoton microscopy of host-pathogen interactions. Cell Host Microbe 5, 13-21 (2009).
3. Berger, E. A., Murphy, P. M. & Farber, J. M. Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. Annu. Rev. Immunol. 17, 657-700 (1999).
4. Lee, B. & Montaner, L. J. Chemokine immunobiology in HIV-1 pathogenesis. J. Leukoc. Biol. 65, 552-565 (1999).
5. Greve, J. M. et al. The major human rhinovirus receptor is ICAM-1. Cell 56, 839-847 (1989).
6. Tosi, M. F. et al. Induction of ICAM-1 expression on human airway epithelial cells by inflammatory cytokines: effects on neutrophil-epithelial cell adhesion. Am. J. Respir. Cell Mol. Biol. 7, 214-221 (1992).
7. Schneider-Schaulies, J. Cellular receptors for viruses: links to tropism and pathogenesis. J. Gen. Virol. 81, 1413-1429 (2000).
8. McFadden, G. Poxvirus tropism. Nature Rev. Microbiol. 3, 201-213 (2005).
9. Bieniasz, P. D. Intrinsic immunity: a front-line defense against viral attack. Nature Immunol. 5, 1109-1115 (2004).
10. Ida-Hosonuma, M. et al. The alpha/beta interferon response controls tissue tropism and pathogenicity of poliovirus. J. Virol. 79, 4460-4469 (2005).
11. O'Shea, J. J. & Murray, P. J. Cytokine signaling modules in inflammatory responses. Immunity 28, 477-487 (2008).
12. Tato, C. M. & Cua, D. J. Snapshot: cytokines IV. Cell 132, 1062.e1-1062.e2 (2008).
13. Tato, C. M. & Cua, D. J. Snapshot: cytokines III. Cell 132, 900 (2008).
14. Tato, C. M. & Cua, D. J. Snapshot: cytokines II. Cell 132, 500 (2008).
15. Tato, C. M. & Cua, D. J. Snapshot: cytokines I. Cell 132, 324.e1-324.e2 (2008).
16. Randall, R. E. & Goodbourn, S. Interferons and viruses: an interplay between induction, signalling, antiviral responses and virus countermeasures. J. Gen. Virol. 89, 1-47 (2008).
17. Stetson, D. B. & Medzhitov, R. Antiviral defense: interferons and beyond. J. Exp. Med. 203, 1837-1841 (2006).
18. Pestka, S., Krause, C. D. & Walter, M. R. Interferons, interferon-like cytokines, and their receptors. Immunol. Rev. 202, 8-32 (2004).
19. Dumoutier, L. et al. Role of the interleukin (IL)-28 receptor tyrosine residues for antiviral and antiproliferative activity of IL-29/interferon-a;1: similarities with type I interferon signaling. J. Biol. Chem. 279, 32269-32274 (2004).
20. Kotenko, S. V. et al. IFN-a;s mediate antiviral protection through a distinct class II cytokine receptor complex. Nature Immunol. 4, 69-77 (2003).
21. Kotenko, S. V. & Langer, J. A. Full house: 12 receptors for 27 cytokines. Int. Immunopharmacol. 4, 593-608 (2004).
22. Doyle, S. E. et al. Interleukin-29 uses a type 1 interferon-like program to promote antiviral responses in human hepatocytes. Hepatology 44, 896-906 (2006).
23. Marcello, T. et al. Interferons a and \ inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics. Gastroenterology 131, 1887-1898 (2006).
24. Sadler, A. J., Latchoumanin, O., Hawkes, D., Mak, J. & Williams, B. R. An antiviral response directed by PKR phosphorylation of the RNA helicase A. PLoS Pathog. 5, e1000311 (2009).
25. Stark, G. R., Kerr, I. M., Williams, B. R., Silverman, R. H. & Schreiber, R. D. How cells respond to interferons. Annu. Rev. Biochem. 67, 227-264 (1998).
26. Meurs, E., Krause, D., Robert, N., Silverman, R. H. & Hovanessian, A. G. The 2-5A system in control and interferon-treated K/BALB cells infected with encephalomyocarditis virus. Prog. Clin. Biol. Res. 202, 307-315 (1985).
27. Meurs, E. F. et al. Constitutive expression of human double-stranded RNA-activated p68 kinase in murine cells mediates phosphorylation of eukaryotic initiation factor 2 and partial resistance to encephalomyocarditis virus growth. J. Virol. 66, 5805-5814 (1992).
28. Arnheiter, H. & Meier, E. Mx proteins: antiviral proteins by chance or by necessity? New Biol. 2, 851-857 (1990).
29. Pavlovic, J., Schroder, A., Blank, A., Pitossi, F. & Staeheli, P. Mx proteins: GTPases involved in the interferon-induced antiviral state. Ciba Found. Symp. 176, 233-243 (1993).
30. Stetson, D. B. & Medzhitov, R. Type I interferons in host defense. Immunity 25, 373-381 (2006).
31. Muller, U. et al. Functional role of type I and type II interferons in antiviral defense. Science 264, 1918-1921 (1994).
32. Finlay, B. B. & McFadden, G. Anti-immunology: evasion of the host immune system by bacterial and viral pathogens. Cell 124, 767-782 (2006).
33. Isaacs, A. & Lindenmann, J. Virus interference. I. The interferon. Proc. R. Soc. Lond. B Biol. Sci. 147, 258-267 (1957).
34. Gondois-Rey, F et al. Hepatitis C virus is a weak inducer of interferon a in plasmacytoid dendritic cells in comparison with influenza and human herpesvirus type-1. PLoS One 4, e4319 (2009).
35. Krug, A. et al. Identification of CpG oligonucleotide sequences with high induction of IFN-a/p in plasmacytoid dendritic cells. Eur. J. Immunol. 31, 2154-2163 (2001).
36. Libri, N. A., Barker, S. J., Rosenberg, W M. & Semper, A. E. A class C CpG toll-like receptor 9 agonist successfully induces robust interferon-alpha production by plasmacytoid dendritic cells from patients chronically infected with hepatitis C. J. Viral Hepat. 16, 315-324 (2009).
37. van Boxel-Dezaire, A. H., Rani, M. R. & Stark, G. R. Complex modulation of cell type-specific signaling in response to type I interferons. Immunity 25, 361-372 (2006).
38. Fiette, L. et al. Theiler's virus infection of 129Sv mice that lack the interferon alpha/beta or interferon gamma receptors. J. Exp. Med. 181, 2069-2076 (1995).
39. Wang, F et al. Disruption of Erk-dependent type I interferon induction breaks the myxoma virus species barrier. Nature Immunol. 5, 1266-1274 (2004).
40. Mrkic, B. et al. Measles virus spread and pathogenesis in genetically modified mice. J. Virol. 72, 7420-7427 (1998).
41. Steinhoff, U. et al. Antiviral protection by vesicular stomatitis virus-specific antibodies in alpha/beta interferon receptor-deficient mice. J. Virol. 69, 2153-2158 (1995).
42. Garcia-Sastre, A. et al. The role of interferon in influenza virus tissue tropism. J. Virol. 72, 8550-8558 (1998).
43. Ryman, K. D., Klimstra, W. B., Nguyen, K. B., Biron, C. A. & Johnston, R. E. Alpha/beta interferon protects adult mice from fatal Sindbis virus infection and is an important determinant of cell and tissue tropism. J. Virol. 74, 3366-3378 (2000).
44. Wessely, R., Klingel, K., Knowlton, K. U. & Kandolf, R. Cardioselective infection with coxsackievirus B3 requires intact type I interferon signaling: implications for mortality and early viral replication. Circulation 103, 756-761 (2001).
45. Samuel, M. A. & Diamond, M. S. Alpha/beta interferon protects against lethal West Nile virus infection by restricting cellular tropism and enhancing neuronal survival. J. Virol. 79, 13350-13361 (2005).
46. Ireland, D. D., Stohlman, S. A., Hinton, D. R., Atkinson, R. & Bergmann, C. C. Type I interferons are essential in controlling neurotropic coronavirus infection irrespective of functional CD8 T cells. J. Virol. 82, 300-310 (2008).
47. Samuel, M. A. et al. PKR and RNase L contribute to protection against lethal West Nile Virus infection by controlling early viral spread in the periphery and replication in neurons. J. Virol. 80, 7009-7019 (2006).
48. Ryman, K. D. et al. Sindbis virus translation is inhibited by a PKR/RNase L-independent effector induced by alpha/beta interferon priming of dendritic cells. J. Virol. 79, 1487-1499 (2005).
49. Ryman, K. D., White, L. J., Johnston, R. E. & Klimstra, W. B. Effects of PKR/RNase L-dependent and alternative antiviral pathways on alphavirus replication and pathogenesis. Viral Immunol. 15, 53-76 (2002).
50. Tesfay, M. Z. et al. Alpha/beta interferon inhibits cap-dependent translation of viral but not cellular mRNA by a PKR-independent mechanism. J. Virol. 82, 2620-2630 (2008).
51. Duan, X., Nauwynck, H. J. & Pensaert, M. B. Effects of origin and state of differentiation and activation of monocytes/macrophages on their susceptibility to porcine reproductive and respiratory syndrome virus (PRRSV). Arch. Virol. 142, 2483-2497 (1997).
52. Delputte, P. L., Van Breedam, W., Barbe, F., Van Reeth, K. & Nauwynck, H. J. IFN-α treatment enhances porcine Arterivirus infection of monocytes via upregulation of the porcine Arterivirus receptor sialoadhesin. J. Interferon Cytokine Res. 27, 757-766 (2007).
53. Meerts, P. , Misinzo, G. & Nauwynck, H. J. Enhancement of porcine circovirus 2 replication in porcine cell lines by IFN-γ before and after treatment and by IFN-α after treatment. J. Interferon Cytokine Res. 25, 684-693 (2005).
54. Navarini, A. A. et al. Increased susceptibility to bacterial superinfection as a consequence of innate antiviral responses. Proc. Natl Acad. Sci. USA 103, 15535-15539 (2006).
55. Schroder, K., Hertzog, P. J., Ravasi, T. & Hume, D. A. Interferon-γ: an overview of signals, mechanisms and functions. J. Leukoc. Biol. 75, 163-189 (2004).
56. van Boxel-Dezaire, A. H. & Stark, G. R. Cell type-specific signaling in response to interferon-γ. Curr. Top. Microbiol. Immunol. 316, 119-154 (2007).
57. Young, H. A. & Bream, J. H. IFN-γ: recent advances in understanding regulation of expression, biological functions, and clinical applications. Curr. Top. Microbiol. Immunol. 316, 97-117 (2007).
58. Kundig, T. M., Hengartner, H. & Zinkernagel, R. M. T cell-dependent IFN-γ exerts an antiviral effect in the central nervous system but not in peripheral solid organs. J. Immunol. 150, 2316-2321 (1993). This study is the first to show that IFNγ induces antiviral effects in a tissue-dependent manner.
59. Trilling, M. et al. Gamma interferon-induced interferon regulatory factor 1-dependent antiviral response inhibits vaccinia virus replication in mouse but not human fibroblasts. J. Virol. 83, 3684-3695 (2009).
60. Binder, G. K. & Griffin, D. E. Interferon-gamma-mediated site-specific clearance of alphavirus from CNS neurons. Science 293, 303-306 (2001). This study shows that IFNγ acts in a tissue-dependent manner to clear alphavirus from the CNS and thereby control viral tropism.
61. Burdeinick-Kerr, R., Govindarajan, D. & Griffin, D. E. Noncytolytic clearance of sindbis virus infection from neurons by gamma interferon is dependent on Jak/ STAT signaling. J. Virol. 83, 3429-3435 (2009).
62. Parra, B. et al. IFN-γ is required for viral clearance from central nervous system oligodendroglia. J. Immunol. 162, 1641-1647 (1999).
63. Sheppard, P. et al. IL-28, IL-29 and their class II cytokine receptor IL-28R. Nature Immunol. 4, 63-68 (2003).
64. Ank, N., West, H. & Paludan, S. R. IFN-a;: novel antiviral cytokines. J. Interferon Cytokine Res. 26, 373-379 (2006).
65. Sommereyns, C., Paul, S., Staeheli, P. & Michiels, T. IFN-lambda (IFN-a;) is expressed in a tissue-dependent fashion and primarily acts on epithelial cells in vivo. PLoS Pathog. 4, e1000017 (2008).
66. Wang, F. et al. RIG-I mediates the co-induction of tumor necrosis factor and type I interferon elicited by myxoma virus in primary human macrophages. PLoS Pathog. 4, e1000099 (2008).
67. Wang, J. et al. Differentiated human alveolar type II cells secrete antiviral IL-29 (IFN-a;1) in response to influenza A infection. J. Immunol. 182, 1296-1304 (2009).
68. Bartlett, N. W., Buttigieg, K., Kotenko, S. V. & Smith, G. L. Murine interferon lambdas (type III interferons) exhibit potent antiviral activity in vivo in a poxvirus infection model. J. Gen. Virol. 86, 1589-1596 (2005).
69. Mordstein, M. et al. Interferon-a; contributes to innate immunity of mice against influenza A virus but not against hepatotropic viruses. PLoS Pathog. 4, e1000151 (2008).
70. Benedict, C. A., Banks, T. A. & Ware, C. F. Death and survival: viral regulation of TNF signaling pathways. Curr. Opin. Immunol. 15, 59-65 (2003).
71. Rahman, M. M. & McFadden, G. Modulation of tumor necrosis factor by microbial pathogens. PLoS Pathog. 2, e4 (2006).
72. Ihnatko, R. & Kubes, M. TNF signaling: early events and phosphorylation. Gen. Physiol. Biophys. 26, 159-167 (2007).
73. Mestan, J. et al. Antiviral effects of recombinant tumour necrosis factor in vitro. Nature 323, 816-819 (1986).
74. Wong, G. H. & Goeddel, D. V. Tumour necrosis factors alpha and beta inhibit virus replication and synergize with interferons. Nature 323, 819-822 (1986).
75. Bartee, E., Mohamed, M. R., Lopez, M. C., Baker, H. V. & McFadden, G. The addition of tumor necrosis factor plus beta interferon induces a novel synergistic antiviral state against poxviruses in primary human fibroblasts. J. Virol. 83, 498-511 (2009).
76. Bergelson, J. M. et al. Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science 275, 1320-1323 (1997).
77. Carson, S. D., Hobbs, J. T. , Tracy, S. M. & Chapman, N. M. Expression of the coxsackievirus and adenovirus receptor in cultured human umbilical vein endothelial cells: regulation in response to cell density. J. Virol. 73, 7077-7079 (1999).
78. Vincent, T. , Pettersson, R. F. , Crystal, R. G. & Leopold, P. L. Cytokine-mediated downregulation of coxsackievirus-adenovirus receptor in endothelial cells. J. Virol. 78, 8047-8058 (2004).
79. Bailer, R. T. , Lee, B. & Montaner, L. J. IL-13 and TNF-α inhibit dual-tropic HIV-1 in primary macrophages by reduction of surface expression of CD4, chemokine receptors CCR5, CXCR4 and post-entry viral gene expression. Eur. J. Immunol. 30, 1340-1349 (2000).
80. Takano, T. , Hohdatsu, T. , Toda, A., Tanabe, M. & Koyama, H. TNF-α, produced by feline infectious peritonitis virus (FIPV)-infected macrophages, upregulates expression of type II FIPV receptor feline aminopeptidase N in feline macrophages. Virology 364, 64-72 (2007).
81. Moutabarrik, A. et al. Cytokine-mediated regulation of the surface expression of complement regulatory proteins, CD46(MCP), CD55(DAF), and CD59 on human vascular endothelial cells. Lymphokine Cytokine Res. 12, 167-172 (1993).
82. Krautkramer, E. & Zeier, M. Hantavirus causing hemorrhagic fever with renal syndrome enters from the apical surface and requires decay-accelerating factor (DAF/CD55). J. Virol. 82, 4257-4264 (2008).
83. Herzberg, F. et al. IL-4 and TNF-α induce changes in integrin expression and adhesive properties and decrease the lung-colonizing potential of HT-29 colon carcinoma cells. Clin. Exp. Metastasis 14, 165-175 (1996).
84. Nista, A., Mattioni, M., Gismondi, A., Palmieri, G. & Santoni, A. (31 -Integrin expression and function in human bladder cancer cells: modulation by TNFa. Anticancer Res. 16, 581-588 (1996).
85. Feire, A. L, Koss, H. & Compton, T. Cellular integrins function as entry receptors for human cytomegalovirus via a highly conserved disintegrin-like domain. Proc. Natl Acad. Sci. USA 101, 15470-15475 (2004).
86. Vana, G. & Westover, K. M. Origin of the 1918 Spanish influenza virus: a comparative genomic analysis. Mol. Phylogenet. Evol. 47, 1100-1110 (2008).
87. Wang, L. F. et al. Review of bats and SARS. Emerg. Infect. Dis. 12, 1834-1840 (2006).
88. Holmes, E. C. On the origin and evolution of the human immunodeficiency virus (HIV). Biol. Rev. Camb. Philos. Soc. 76, 239-254 (2001).
89. Baxby, D. & Bennett, M. Poxvirus zoonoses. J. Med Microbiol. 46, 17-20, 28-33 (1997).
90. Hawranek, T. et al. Feline orthopoxvirus infection transmitted from cat to human. J. Am. Acad. Dermatol. 49, 513-518 (2003).
91. Lewis-Jones, S. Zoonotic poxvirus infections in humans. Curr. Opin. Infect. Dis. 17, 81-89 (2004).
92. Schupp, P. et al. Cowpox virus in a 12-year-old boy: rapid identification by an orthopoxvirus-specific polymerase chain reaction. Br. J. Dermatol. 145, 146-150 (2001).
93. CDC. Outbreak of swine-origin influenza A (H1 N1) virus infection - Mexico, March-April 2009. Morb. Mortal. Wkly Rep 58, 467- 470 (2009).
94. Sidwell, R. W. et al. Antiviral and immunomodulating inhibitors of experimentally-induced Punta Toro virus infections. Antiviral Res. 25, 105-122 (1994).
95. Morrill, J. C, Czarniecki, C. W. & Peters, C. J. Recombinant human interferon-y modulates Rift Valley fever virus infection in the rhesus monkey. J. Interferon Res. 11, 297-304 (1991).
96. Morrill, J. C, Jennings, G. B., Cosgriff, T. M., Gibbs, P. H. & Peters, C. J. Prevention of Rift Valley fever in rhesus monkeys with interferon-a. Rev. Infect. Dis. 11 , S815-S825 (1989).
97. Subramanian, G. M. et al. Potent in vitro activity of the albumin fusion type 1 interferons (albumin-interferon-a and albumin-interferon-p) against RNA viral agents of bioterrorism and the severe acute respiratory syndrome (SARS) virus. Chemotherapy 54, 176-180 (2008).
98. Pinto, A. J., Morahan, P. S., Brinton, M., Stewart, D. & Gavin, E. Comparative therapeutic efficacy of recombinant interferons-a, -(3, and -y against alphatogavirus, bunyavirus, flavivirus, and herpesvirus infections. J. Interferon Res. 10, 293-298 (1990).
99. Pinto, A. J., Morahan, P. S. & Brinton, M. A. Comparative study of various immunomodulators for macrophage and natural killer cell activation and antiviral efficacy against exotic RNA viruses. Int. J. Immunopharmacol. 10, 197-209 (1988).
100. Kelly, E. & Russell, S. J. History of oncolytic viruses: genesis to genetic engineering. Mol. Ther. 15, 651-659 (2007).
101. Liu, T. C., Galanis, E. & Kirn, D. Clinical trial results with oncolytic virotherapy: a century of promise, a decade of progress. Nature Clin. Pract. Oncol. 4, 101-117 (2007).
102. Vaha-Koskela, M. J., Heikkila, J. E. & Hinkkanen, A. E. Oncolytic viruses in cancer therapy. Cancer Lett. 254, 178-216 (2007).
103. Barber, G. N. Vesicular stomatitis virus as an oncolytic vector. Viral Immunol. 17, 516-527 (2004).
104. Bartee, E. & McFadden, G. Human cancer cells have specifically lost the ability to induce the synergistic state caused by tumor necrosis factor plus interferon-β. Cytokine 28 July 2009 (doi:10.1016/ j.cyto.2009.06.006).
105. Stanford, M. M. et al. Myxoma virus oncolysis of primary and metastatic B16F10 mouse tumors in vivo. Mol. Ther. 16, 52-59 (2008).
106. Stojdl, D. F. et al. Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus. Nature Med. 6, 821-825 (2000).
107. Cattaneo, R., Miest, T. , Shashkova, E. V. & Barry, M. A. Reprogrammed viruses as cancer therapeutics: targeted, armed and shielded. Nature Rev. Microbiol. 6, 529-540 (2008).
108. Muster, T. et al. Interferon resistance promotes oncolysis by influenza virus NS1-deletion mutants. Int. J. Cancer 110 , 15-21 (2004).
109. Egorov, A. et al. Transfectant influenza A viruses with long deletions in the NS1 protein grow efficiently in Vero cells. J. Virol. 72, 6437-6441 (1998).
110. Garcia-Sastre, A. et al. Influenza A virus lacking the NS1 gene replicates in interferon-deficient systems. Virology 252, 324-330 (1998).
111. Lee, B. et al. Oncolysis of human gastric cancers by an E1B 55 kDa-deleted YKL-1 adenovirus. Cancer Lett. 185, 225-233 (2002).
112. Nemunaitis, J. et al. Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: a phase II trial. Cancer Res. 60, 6359-6366 (2000).
113. Kirn, D. H., Wang, Y., Le Boeuf, F., Bell, J. & Thorne, S. H. Targeting of interferon-beta to produce a specific, multi-mechanistic oncolytic vaccinia virus. PLoS Med. 4, e353 (2007).
114. Shashkova, E. V., Spencer, J. F., Wold, W. S. & Doronin, K. Targeting interferon-alpha increases antitumor efficacy and reduces hepatotoxicity of E1A-mutated spread-enhanced oncolytic adenovirus. Mol. Ther. 15, 598-607 (2007).
115. Shashkova, E. V., Kuppuswamy, M. N., Wold, W. S. & Doronin, K. Anticancer activity of oncolytic adenovirus vector armed with IFN-α and ADP is enhanced by pharmacologically controlled expression of TRAIL. Cancer Gene Ther. 15, 61-72 (2008).
116. Hevehan, D. L., Miller, W. M. & Papoutsakis, E. T. Differential expression and phosphorylation of distinct STAT3 proteins during granulocytic differentiation. Blood 99, 1627-1637 (2002).
117. Bartee, E., Mohamed, M. R. & McFadden, G. Tumor necrosis factor and interferon: cytokines in harmony. Curr. Opin. Microbiol. 11 , 378-383 (2008).
118. Tang, H., Banks, K. E., Anderson, A. L. & McLachlan, A. Hepatitis B virus transcription and replication. Drug News Perspect. 14, 325-334 (2001).
119. van Riel, D. et al. Human and avian influenza viruses target different cells in the lower respiratory tract of humans and other mammals. Am. J. Pathol. 171, 1215-1223 (2007).
120. Lopez-Guerrero, J. A., Rayet, B., Tuynder, M., Rommelaere, J. & Dinsart, C. Constitutive activation of U937 promonocytic cell clones selected for their resistance to parvovirus H-1 infection. Blood 89, 1642-1653 (1997).
121. Steed, A., Buch, T. , Waisman, A. & Virgin, H. W. T. Gamma interferon blocks gammaherpesvirus reactivation from latency in a cell type-specific manner. J. Virol. 81, 6134-6140 (2007).